Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chemotherapy Plus Lapatinib or Trastuzumab or Both in Her2+ Primary Breast Cancer. A Randomized Phase IIb Study With Biomarker Evaluation

Next Previous
Trial Profile

Chemotherapy Plus Lapatinib or Trastuzumab or Both in Her2+ Primary Breast Cancer. A Randomized Phase IIb Study With Biomarker Evaluation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Methotrexate; Paclitaxel; Trastuzumab
  • Indications Early breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Acronyms CHER-LOB
  • Sponsors GlaxoSmithKline

    • Most Recent Events

    • 07 Sep 2023 Results from ShortHER trial, CherLOB , evaluating how molecular heterogeneity affects the pattern of distant relapse in HER2-positive BC, published in the Journal of the National Cancer Institute
    • 18 Jun 2021 Results of post-hoc survival analysis assessing long-term survival outcomes published in the European Journal of Cancer
    • 31 May 2020 Primary endpoint (Percentage of Participants With Pathological Complete Response (pCR) in the Breast and in the Lymph Nodes) has been met, as per Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top